These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 215338)

  • 21. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
    Vecchio TJ; Linden CV; O'Connell MJ; Heilman J
    Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.
    Kane JP; Malloy MJ; Tun P; Phillips NR; Freedman DD; Williams ML; Rowe JS; Havel RJ
    N Engl J Med; 1981 Jan; 304(5):251-8. PubMed ID: 7003391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
    Weisweiler P; Merk W; Jacob B; Schwandt P
    Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
    Seplowitz AH; Smith FR; Berns L; Eder HA; Goodman DS
    Atherosclerosis; 1981 Apr; 39(1):35-43. PubMed ID: 7018502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins.
    Witztum JL; Schonfeld G; Weidman SW; Giese WE; Dillingham MA
    Metabolism; 1979 Mar; 28(3):221-9. PubMed ID: 216884
    [No Abstract]   [Full Text] [Related]  

  • 27. Primary hypercholesterolemia: effect of treatment on serum lipids, lipoprotein fractions, cholesterol absorption, sterol balance, and platelet aggregation.
    Briones ER; Steiger D; Palumbo PJ; Kottke BA
    Mayo Clin Proc; 1984 Apr; 59(4):251-7. PubMed ID: 6708603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probucol with colestipol in the treatment of hypercholesterolemia.
    Dujovne CA; Krehbiel P; Decoursey S; Jackson B; Chernoff SB; Pitterman A; Garty M
    Ann Intern Med; 1984 Apr; 100(4):477-82. PubMed ID: 6367578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
    Illingworth DR
    Ann Intern Med; 1984 Nov; 101(5):598-604. PubMed ID: 6567462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Low dose" colestipol in children, adolescents and young adults with familial hypercholesterolemia.
    Schlierf G; Mrozik K; Heuck CC; Middelhoff G; Oster P; Riesen W; Schellenberg B
    Atherosclerosis; 1982 Jan; 41(1):133-8. PubMed ID: 7073790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiography for study of lipid-lowering therapy.
    Blankenhorn DH; Sanmarco ME
    Circulation; 1979 Feb; 59(2):212-4. PubMed ID: 758988
    [No Abstract]   [Full Text] [Related]  

  • 32. Low-dose colestipol plus probucol for hypercholesterolemia.
    Dujovne CA; Chernoff SB; Krehbiel P; Jackson B; DeCoursey S; Taylor H
    Am J Cardiol; 1984 Jun; 53(11):1514-8. PubMed ID: 6375337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up.
    Ojala JP; Helve E; Karjalainen K; Tarkkanen A; Tikkanen MJ
    Atherosclerosis; 1990 May; 82(1-2):85-95. PubMed ID: 2360923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of colestipol on the metabolism of very-low-density lipoproteins in man.
    Witztum JL; Schonfeld G; Weidman SW
    J Lab Clin Med; 1976 Dec; 88(6):1008-18. PubMed ID: 186544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia.
    Groot PH; Dijkhuis-Stoffelsma R; Grose WF; Ambagtsheer JJ; Fernandes J
    Acta Paediatr Scand; 1983 Jan; 72(1):81-5. PubMed ID: 6407278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dietary treatment on the lipid, lipoprotein and fatty acid compositions in type IV familial hypertriglyceridemia.
    Agheli N; Cloarec M; Jacotot B
    Ann Nutr Metab; 1991; 35(5):261-73. PubMed ID: 1776822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xanthomatosis and hyperlipoproteinemia; a review.
    Polano MK
    Dermatologica; 1974; 149(1):1-9. PubMed ID: 4372111
    [No Abstract]   [Full Text] [Related]  

  • 39. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.
    Malloy MJ; Kane JP; Kunitake ST; Tun P
    Ann Intern Med; 1987 Nov; 107(5):616-23. PubMed ID: 3662275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diet and drug treatment of hyperlipidemia and atherosclerosis.
    Kuo PT
    Ann Clin Lab Sci (1971); 1972; 2(4):322-4. PubMed ID: 4342101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.